Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.

Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I

NCT00171925 ·Status: TERMINATED ·Phase: PHASE3

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

NCT00330759 ·Status: COMPLETED ·Phase: PHASE3

Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy

NCT00972959 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

NCT06221072 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma

NCT00432458 ·Status: COMPLETED ·Phase: PHASE3

Bone Demineralization Lesions in the Injured Marrow: Efficacy and Tolerability of Administration Early and Repeated the Zoledronic Acid. Comparative Study, Prospective, Double-blind Controlled (DBMZol)

NCT01802658 ·Status: TERMINATED ·Phase: PHASE3

Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma

NCT00263484 ·Status: COMPLETED ·Phase: PHASE2

Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders

NCT00258258 ·Status: TERMINATED ·Phase: PHASE1

Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma

NCT01142232 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma

NCT06517017 ·Status: RECRUITING ·Phase: PHASE2

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

NCT03289299 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

NCT02312258 ·Status: COMPLETED ·Phase: PHASE3

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

NCT00644228 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

NCT02516423 ·Status: UNKNOWN ·Phase: PHASE3

Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients

NCT02308280 ·Status: COMPLETED ·Phase: PHASE2

MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma

NCT03489525 ·Status: COMPLETED ·Phase: PHASE1

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01055301 ·Status: WITHDRAWN ·Phase: PHASE2

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

NCT04035226 ·Status: COMPLETED

Prolonged Protection From Bone Disease in Multiple Myeloma

NCT02286830 ·Status: COMPLETED ·Phase: PHASE4

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

NCT01428492 ·Status: COMPLETED ·Phase: PHASE1

A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients

NCT00752518 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma

NCT01160484 ·Status: COMPLETED ·Phase: PHASE2

Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

NCT00288028 ·Status: COMPLETED ·Phase: PHASE1

Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

NCT01531998 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse

NCT01087008 ·Status: COMPLETED ·Phase: PHASE4